HomeAI · summaries
Storia in 2 fonti
Despite 'decent' data, Verastem rethinks options for approved oncology combo in pancreatic cancer
With good-but-not-great updated data on its approved oncology combo of avutometinib plus defactinib (A+D) in first-line metastatic pancreatic cancer, Verastem Oncology will now channel its primary | With good-but-not-great updated data on its approved oncology combo of avutometinib plus defactinib in first-line metastatic pancreatic cancer, Verastem Oncology will now channel its primary R&D efforts toward other pipeline darlings.
Confronto fonti
2 prospettive sulla stessa storiaTimeline cronologica
- ·
morningstar.com
Verastem Oncology Announces Positive Updated Results from RAMP 205 Evaluating Avutometinib Plus Defactinib in Combination with…
Verastem Oncology Announces Positive Updated Results from RAMP 205 Evaluating Avutometinib Plus Defactinib in Combination with Standard-of-Care Chemotherapy in First-Line…
- ·
fiercepharma.com
Despite 'decent' data, Verastem rethinks options for approved oncology combo in pancreatic cancer
With good-but-not-great updated data on its approved oncology combo of avutometinib plus defactinib (A+D) in first-line metastatic pancreatic cancer, Verastem Oncology will now…